AtriCure’s (ATRC) Market Outperform Rating Reiterated at JMP Securities

JMP Securities reiterated their market outperform rating on shares of AtriCure (NASDAQ:ATRC) in a research report sent to investors on Monday,Benzinga reports. The firm currently has a $60.00 price target on the medical device company’s stock.

ATRC has been the topic of several other reports. UBS Group increased their price objective on shares of AtriCure from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Oppenheimer increased their price objective on shares of AtriCure from $32.00 to $36.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. restated an “overweight” rating and issued a $40.00 price target on shares of AtriCure in a report on Tuesday, December 17th. Needham & Company LLC raised their price target on shares of AtriCure from $40.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday, January 22nd. Finally, Canaccord Genuity Group raised their price target on shares of AtriCure from $53.00 to $61.00 and gave the company a “buy” rating in a report on Monday, December 9th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, AtriCure has a consensus rating of “Moderate Buy” and a consensus price target of $46.44.

AtriCure Price Performance

NASDAQ:ATRC opened at $42.36 on Monday. The firm has a market cap of $2.07 billion, a price-to-earnings ratio of -51.04 and a beta of 1.46. AtriCure has a 12-month low of $18.94 and a 12-month high of $43.11. The company has a current ratio of 3.62, a quick ratio of 2.59 and a debt-to-equity ratio of 0.13. The company’s 50-day moving average is $35.39 and its two-hundred day moving average is $31.09.

Institutional Trading of AtriCure

Several large investors have recently bought and sold shares of the company. Champlain Investment Partners LLC grew its position in shares of AtriCure by 4.3% during the third quarter. Champlain Investment Partners LLC now owns 2,790,758 shares of the medical device company’s stock worth $78,253,000 after buying an additional 115,813 shares in the last quarter. Wellington Management Group LLP grew its position in shares of AtriCure by 0.4% during the third quarter. Wellington Management Group LLP now owns 1,543,896 shares of the medical device company’s stock worth $43,291,000 after buying an additional 6,045 shares in the last quarter. State Street Corp grew its position in shares of AtriCure by 4.9% during the third quarter. State Street Corp now owns 1,344,856 shares of the medical device company’s stock worth $37,710,000 after buying an additional 63,002 shares in the last quarter. Geode Capital Management LLC grew its position in shares of AtriCure by 2.9% during the third quarter. Geode Capital Management LLC now owns 1,152,628 shares of the medical device company’s stock worth $32,326,000 after buying an additional 32,676 shares in the last quarter. Finally, Two Sigma Advisers LP boosted its holdings in AtriCure by 14.6% in the third quarter. Two Sigma Advisers LP now owns 664,100 shares of the medical device company’s stock worth $18,621,000 after purchasing an additional 84,700 shares during the period. Institutional investors and hedge funds own 99.11% of the company’s stock.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.